Kyowa Kirin CoKYKOF 82 Net Margin % is 23.37% as of Dec. 2025, which is 65% above its 10-year median of 14.13. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.92 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 956 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 76.78% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Kyowa Kirin Co's Net Income for the
three
months ended in Dec. 2025 was $221 Mil. Kyowa Kirin Co's Revenue for the
three
months ended in Dec. 2025 was $945 Mil. Therefore, Kyowa Kirin Co's net margin for the quarter that ended in Dec. 2025 was 23.37%.
The historical rank and industry rank for Kyowa Kirin Co's Net Margin % or its related term are showing as below:
KYKOF'
s Net Margin % Range Over the Past 10 Years
Min: 8.75 Med: 14.13 Max: 21.94
Current: 14.28
KYKOF's Net Margin % is ranked better than 76.78% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs KYKOF: 14.28
Kyowa Kirin Co (OTCPK:KYKOF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Kyowa Kirin Co Net Margin % Related Terms
Kyowa Kirin Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a Net Margin % of 23.37% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Kyowa Kirin Co and its competitors. This is 65% above median its historical median of 14.13. Over the past decade, Kyowa Kirin Co's Net Margin % has ranged from 8.75 to 21.94. According to the industry distribution chart, Kyowa Kirin Co ranks #222 out of 956 companies in the Drug Manufacturers industry, placing it in the top 23.2%.
Is Kyowa Kirin Co's Net Margin % too high?
Kyowa Kirin Co's current Net Margin % of 23.37% is 65% above median its 10-year median of 14.13. Over the past 10 years, this metric has ranged from a low of 8.75 to a high of 21.94. The Drug Manufacturers industry median Net Margin % is 5.56. Kyowa Kirin Co's value of 23.37% is 320.3% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #222 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #222 out of 956 companies for Net Margin %. This places Kyowa Kirin Co in the top 23% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Kyowa Kirin Co's value of 23.37% is 320.3% above this benchmark. Historically, Kyowa Kirin Co's own Net Margin % has ranged from 8.75 to 21.94 over the past decade. While the company's 10-year median is 14.13 vs. the industry median of 5.56, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current Net Margin % of 23.37% is 320.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Net Margin % is 23.37%, which is 65% above median its own 10-year median of 14.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.92, compared to a current price of $14.43 — trading 19.5% below its estimated fair value. The current Net Margin % is 23.37%, which is 65% above median its 10-year median of 14.13 and 320.3% above the Drug Manufacturers industry median of 5.56. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Net Margin % is 23.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 19.5% below its estimated GF Value™ of $17.92.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
Net Margin %: 23.37% (65% above median its 10-year median of 14.13)
GF Value™: $17.92 vs. price of $14.43 (19.5% below fair value)
Industry Position: 320.3% above the Drug Manufacturers median (#222 of 956)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
